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OSA1Spontaneous tumors in dogs share many of the same features of their human orthologues including clinical
behavior, response to treatment, and molecular defects. It is therefore natural to consider the use of dogs and
their spontaneous malignancies in the study of complex disease such as cancer. Scottish Deerhounds are a
giant breed of dogs that exhibit a high incidence of bone cancer. Our previous work suggested that
osteosarcoma within this breed could be explained by the presence of a major gene of dominant effect.
Herein, we use a whole genome mapping approach to evaluate a four-generation pedigree of Scottish
Deerhounds for linkage of their osteosarcoma phenotype. Using this approach we found evidence of linkage
(Zmax=5.766) between their phenotype and markers located on CFA34, in a region syntenic to human
chromosome 3q26. The identiﬁcation of this locus provides novel insight into the genetic basis of
osteosarcoma in both canines and humans.e, Department of Small Animal
aching Hospital, Knoxville, TN
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.1. Introduction
Osteosarcoma (osteogenic sarcoma, OSA) is the most common
(N85%) primary malignant bone tumor in both humans and canines.
In the United States, approximately 10,000 canine and 800 human
cases of osteosarcoma are diagnosed each year [1–3]. Of the cancers
that occur in both pet dogs and humans, osteosarcoma is perhaps the
most similar. In both species it is histologically composed of
mesenchymal cells that produce osteoid matrix. The dog and human
also share similar anatomic predilections including the distal femur,
proximal tibia, and proximal humerus amongst others. The clinical
behavior in both species is characterized as highly aggressive with
very high rates of metastatic spread. In fact, 85–90% of both humans
and pet dogs are considered to have microscopic metastatic disease at
the time of initial diagnosis [3,4]. Humans and pet dogs also share a
similar response to surgery and chemotherapy regimens. While
dramatic progress has been made in the treatment and outcome in
both species, there is limited understanding of the etiology of the
disease. Because of the many similarities shared by humans and pet
dogs with osteosarcoma, it is only natural to use dogs and their
spontaneous malignancies to more fully understand disease
pathogenesis.
The genetic changes that occur in osteosarcoma have received
considerable attention in recent years in an attempt to elucidateetiology in both humans and canids. In humans, loss of heterozygosity
screening has identiﬁed several chromosomal regions with high
frequencies of allelic loss including chromosomes 3q, 13q, 17p, and
18q [5–8]. Heritable cancer syndromes, although extremely rare, have
been associated with two of these regions; namely chromosomes 13q
(Retinoblastoma) and 17p (Li-Fraumeni) [9]. Comparative genomic
hybridization has also been used to identify regions of genomic
ampliﬁcation in human-origin tumors, including the most common
amplicons at 12q11–q15 and 17p11–13 [10]; while transcriptome
proﬁles of osteosarcoma cell lines has provided information on the
molecular variation between tumors [11]. In dogs, gene expression
studies have identiﬁed proﬁles associated with both tumor progres-
sion [12] and survival [13]. These proﬁles demonstrate strong
similarities between canine and human osteosarcoma along with
potential biologic targets in both species. Comparative genomic
hybridization of canine tumor tissues has also identiﬁed regions of
recurrent cytogenetic changes within select breeds and correlated
these regions with candidate tumor suppressor or oncogenes [14]. In
spite of these advances made in understanding the tumor biology of
both human and canine osteosarcoma, it is unclear what precursor
(germline or heritable) lesions are critical for tumorigenesis.
In the canine population, large and giant breeds of dogs are at
increased risk for the development of OSA; together these breeds
account for the majority (N80%) of reported cases [4]. The Scottish
Deerhound is a giant breed dog ﬁrst recognized by the American
Kennel Club (AKC) in 1886. The overall breed-speciﬁc incidence of
OSA in the Deerhound has been estimated to be greater than 150 cases
per 1,000 dogs (compared to 7 cases per 100,000 dogs in the general
dog population) [4,15]. Given the high incidence of OSA within a
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genetic modiﬁer (locus) for the disease exists within this breed.
In a recent report [16], we described a population of greater than
1,000 Scottish Deerhounds that were ascertained as part of a
prospective health study. Statistical analysis of this population
supported the presence of a “putative” high-risk allele associated
with the development of osteosarcoma. By comparing models of
disease transmission, we were able to show that a highly penetrant,
dominant model was most probable. The frequency of the high-risk
allele in this dominant model was estimated to be 0.128, and only
genotype was found to be correlated with disease onset.
The artiﬁcial selection that has led to this high, breed-speciﬁc,
incidence of OSA can be further utilized to identify the genetic
determinants which regulate disease onset. Speciﬁcally, the inbreed-
ing that has led to this high-incidence of disease also serves to simplify
its transmission properties. While in humans OSA is clearly a complex
disease with no obvious transmission patterns, the canine orthologue
in the Scottish Deerhound exhibits a simple dominant transmission.
Furthermore, with the completion of the canine genome sequencing
project and the availability of high-resolution canine genetic maps,
linkage and association studies can be pursued in canine populations
such as the Scottish Deerhound. Through these mapping studies
candidate loci and genes can be identiﬁed and used to further our
understanding of not only the canine but also the human disease.
In this study, we describe the mapping of the osteosarcoma
phenotype (OSA1) that is segregating in a four-generation pedigree of
Scottish Deerhounds. A whole genome linkage approach is used to
map OSA1 to CFA34, and to exclude other chromosomal regions. The
identiﬁcation of a novel locus for canine osteosarcoma provides
important information on the location of candidate genes for both
canine and human OSA.
2. Materials and methods
2.1. Sample population
Dogs used in this study were all privately owned and AKC
registered Scottish Deerhounds from a larger population previously
described [16]. A four-generation pedigree of Scottish Deerhounds
was selected from this larger population and included 135 dogs; 50 of
whom were identiﬁed as affected with osteosarcoma. DNA samples
were available from a total of 60 dogs in this pedigree, with the
remaining dogs (i.e. 75 dogs) providing phenotypic information that
allowed for the construction of a comprehensive pedigree. Current
and historic health information on all dogswas collected from owners,
breeders, and veterinarians. Affected status was determined by the
presence of characteristic radiographic ﬁndings of aggressive bone
disease and/or histologic examination. Pedigree information and
medical histories were entered into a pedigree management program
(Cyrillic 2.1.3, Cherwell Software). The program PEDINFO was used to
determine descriptive characteristics of the population. This program
is available as a component of the genetic analysis package SAGE 5.2.0
[17]. Inbreeding coefﬁcients were estimated using the Kinship
Matrices option of the genetic software MENDEL 6.01 [18].
Health information collected included a variety of qualitative and
quantitative traits (i.e. covariates). Qualitative traits included OSA
status, presence/absence of other diseases including cancers, and
gender. OSA status had three possible outcomes: affected, unaffected,
or unknown. Quantitative traits included age at exam, age of onset,
height, weight, and length of time sexually intact (as a measure of
cumulative sex hormone exposure). Age at examwas considered to be
the age at last known contact or age at death where applicable. Age of
onset documented the age at which deﬁnitive diagnosis of osteosar-
coma was made in affected individuals. Time was measured in years,
height in inches at the shoulder and weight in pounds. Other
information collected (where applicable) included cause of death,tumor location, and treatment option. All procedures involving
animals in this study were approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of Tennessee.
2.2. DNA samples
EDTA preserved whole blood samples were collected from 60 dogs
in the four generation pedigree. DNA was puriﬁed using standard
methods.
2.3. Markers
An extended microsatellite screening set was used for the whole
genome scan. The microsatellite set included markers previously
identiﬁed in a mapping set referred to as MSS3 [19]; 103 additional
markers (610 total) were selected throughout the genome to increase
coverage of select regions. Marker positions are as noted in the
CanFam 2.0 genome assembly [20]. Average physical spacing of
markers in this extended set was 4.1 Mb. Genetic distances between
markers were obtained from the Canine Genetic LinkageMap [21] and
veriﬁed on this sample population using the software SimWalk2 [22].
2.4. Genotyping
Fluorescent-labeled oligonucleotides were used to amplify poly-
morphic markers used for linkage analysis. Samples were run on a
MegaBace® 1500, 96-capillary array (GE Healthcare) and genotypes
were analyzed using the Genetic Proﬁler software (version 2.2; GE
Healthcare). All genotypes were manually scored with values
converted to simple integers (i.e. 1–9) for statistical analysis.
Genotypes for the 75 untyped dogs were scored as unknown.
2.5. Statistical analyses
Osteosarcoma was considered a dichotomous trait in which
individuals were classiﬁed as “unaffected” (at the time of exam),
“affected”, or in some cases “unknown status”. Individuals listed with
“unknown” phenotypes were included to provide a non-disjoint four-
generation pedigree; the disease phenotypes for these individuals
were ignored for each analysis. Multipoint linkage analysis was
performed on a 64 bit (Xeon) PC computer using the SimWalk2
(v2.91) program [22,23]. SimWalk2 uses a Markov chain Monte Carlo
(MCMC) algorithm and simulated annealing algorithms to avoid
limitations due to sample size or inbreeding. The program was
compiled from source code for usage on a 64-bit platform.
The osteosarcoma phenotype (OSA1) segregating in this pedigree
was modeled as both a dominant and recessive Mendelian trait with
allele frequencies of qa=0.128 and qa=0.501, respectively [16].
Microsatellite marker allele frequencies were obtained from analysis
of a larger population previously described [16]. Recombination
frequencies were assumed to be equal between males and females
due to software limitations. Based on our previous work, multipoint
LOD-score calculations were performed at penetrances of 1.0 and 0.9,
under the assumption of locus homogeneity (alpha=1.0). All other
parameters were set to their default values under SimWalk2. LOD
scores (Zmax or location scores) of ≥3.0 were considered consistent
with linkage. Conversely, LOD scores of ≤−2.0 could be used to
exclude regions from consideration. For comparison, a LOD score
of N3.0 is associated with a genome-wide signiﬁcance level of b0.05 in
favor of linkage [24] while a LOD score of≤−2.0 corresponds to 100:1
odds against linkage [25]. Haplotype analysis was used to determine
the minimal candidate region for location of the osteosarcoma gene.
Haplotypes were estimated using SimWalk2 and illustrated using
Cyrillic 2.1.3.
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3.1. Descriptive analysis
Thirteen sibships comprising a total of 135 dogs were selected
from a previously described population of 1,272 Scottish Deerhounds
[16] (Table 1). These sibships could be arranged into one large four
generation pedigree. DNA samples were available from 60 of the 135
dogs for use in a whole genome scan. The remaining 75 untyped dogs
provided health information only and were used to construct the
comprehensive pedigree. A total of 9 inbreeding loops were identiﬁed
in this pedigree, with an average inbreeding coefﬁcient of 0.086
estimated using the kinship matrices option of MENDEL 6.01. Due to
the graphical complexity, only a small subset of the pedigree is shown
in Fig. 1.
This pedigree included 68 male dogs and 67 female dogs, ranging
in age from 4.0 to 13.6 years. Of these dogs, 50 were conﬁrmed
affected, 83 were unaffected at the time of exam, while 2 had
unknown health status or were lost to followup. A similar gender
distribution was found in the subset of dogs for which DNA samples
were available (32 female and 28 male dogs). This subset, however,
was further enriched with affected individuals including 40 affected
dogs and only 20 dogs who were unaffected at the time of exam. The
absolute percentage of affected dogs amongst all dogs with known
health status in the pedigree was 38% (50/133), which is higher than
the population based prevalence previously reported (i.e. 21%) [16].
Affected dogs ranged in age from 4.9 to 13.6 years with a mean age of
onset of 7.6 years (±1.9 yrs). Unaffected dogs were signiﬁcantly older
than affected dogs (8.5±2.9 yrs, p=0.02). This pedigree of Scottish
Deerhounds compares favorably to the previously described larger
population [16] with no signiﬁcant difference in age of onset, gender
distribution, or gender-speciﬁc prevalence of osteosarcoma (Table 1).
Differences in disease prevalence are directly attributable to pheno-
typic based selection of this pedigree. In other words, this pedigree isTable 1
(A) Descriptive statistics for 135 dogs in 13 families analyzed in this report (current pedigree
used for linkage analysis performed with the SimWalk2 [22] software package.
(A) Descriptive statistics
Current pedigree
Total individuals 135
Males 68
Females 67
Affected 50
Unaffected 82
%Affected 38%
Missing 2
Probands 1
Sibships 13
Sibship size 1–9 (3.0±2.4)
# DNA samples available 60
Inbreeding loops 9
Inbreeding coefﬁcient 0.086
Age (years) 4.0–13.6 (7.7±2.1)
Age of onset (years) 4.9–13.6 (7.6±1.9)
(B) Parameter values
Parameter
Allele frequency
Dominant
Recessive
Penetrance
Complete
Reduced
Alphaa
Mistyping probability
a The a priori proportion of pedigrees that are segregating an affected gene linked to thisenriched with affected individuals which allows for the use of familial
based linkage methodology. Finally, no correlation was found
between height, weight, or duration of gonadal hormone exposure
and osteosarcoma (data not shown); similar to the larger population
[16].
3.2. Linkage analysis
The whole genome linkage data consisted of genotypes from the
60 dogs at the 610 microsatellites identiﬁed from the CanFam 2.0
genome assembly. Multipoint linkage analysis was performed using
SimWalk2 under both dominant and recessive models. Allele
frequencies for the disease allele were set to qa=0.128 and
qa=0.501, for the dominant and recessive model, respectively
(Table 1). These values were based on our previous population-
wide segregation analysis of the disease phenotype (OSA1) [16]. The
resultant parametric multipoint LOD scores are illustrated in Fig. 2.
These scores are based under the assumption of no locus heteroge-
neity within the pedigree and a fully penetrant trait. Similar results
were found with a reduced penetrance of 0.9 (data not shown).
The majority of the genome was excluded from linkage on the
basis of LOD scores b−3.0 (Fig. 2). The regions with LOD scores of N1
but b3 can neither be deﬁnitively excluded from linkage nor are
considered to exhibit strong evidence of linkage. Table 2 shows all
results reaching a signiﬁcance threshold of equivalent logarithm of
odds (LOD) score N1. Regions from chromosomes 1, 15, 22, and 25
exhibited weak evidence of linkage with LOD scores marginally N1
(Table 2). These regions contained markers with relatively low
information content due to high levels of homozygosity. Given the
acrocentric nature of canine chromosomes, each of these four regions
are localized to the most centromeric portion of their respective
chromosomes; regions typically associated with consistently low
recombination rates and heterozygosity across breeds [26]. These
centromeric regions also exhibited low levels of recombination and) compared to a previous report [16] (mean±standard deviation); (B) Parameter values
Phillips et al, 2007 [16]
1057
479
578
211
794
21%
52
5
314
1–11 (3.0±1.9)
672
187
0.032
0.5–14.9 (6.8±2.8)
2–13.9 (7.0±2.0)
Value
0.128
0.501
1.0
0.9
1.0
0.025
set of marker loci. A value of 1.0 assumes genetic homogeneity.
Fig. 1. Deerhound pedigree. Representative subset pedigree of dogs used in this study with known affected status. Standard pedigree symbols are used. Affected individuals are
represented by ﬁlled symbols. Multiple inbreeding (double lines) and mating loops are present. Not all relationships are shown.
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factors which likely contributed to the creation of what are essentially
non-informative chromosomal regions and hampered our ability to
statistically eliminate them. This is a relatively common ﬁnding, to
note regions of extended homozygosity; which are often especially
marked around centromeres [20,21,26].
A region with moderate evidence of linkage (Zmax=2.246) was
found between the osteosarcoma phenotype (OSA1) and markers
located in the telomeric portion of chromosome 18 (Figs. 2 and 3).
This region spans 7 cM between markers REN168H09 and FH2429 and
is characterized by relatively high levels of recombination and
heterozygosity across breeds [20]. In the Scottish Deerhound
population, relatively low levels of recombination were found for
nearly all of chromosome 18; however, a relative increase in
recombination rate was noted in the center of the region of interest
(Fig. 3A). This effect led to the creation of a conserved haplotype block
seen within the affected dogs of this pedigree, which extends to
marker FH2429 of chromosome 18.
Signiﬁcant linkage was found between markers located on
chromosome 34 (CFA34) and the osteosarcoma phenotype in this
pedigree (OSA1). This 40-cM region extends from markers
REN243023 through REN238D23 (Fig. 2). The peak LOD score
(Zmax=5.766) was found at 46.8-cM near marker REN234E12
(Fig. 3B). Using SimWalk2, haplotypes were constructed for chromo-
some 34 (CFA34); estimated haplotypes from the most informative
sibship were then used to identify the critical region for OSA1 (Fig. 4).
Affected individuals shared a common haplotype for markers
spanning this region. Critical recombination events in affected
individuals occurred between markers FH3836 and REN234E12 and
REN173D06 and REN44K21, deﬁning a 10-cM critical interval extend-
ing from marker FH3836 to REN44K21. Several unaffected individuals
demonstrate recombination events that could signiﬁcantly narrow
the critical region. However, because of the reduced penetrance of this
condition [16], one or more of these individuals could still have the
affected allele. To eliminate the potential ambiguity, the critical region
has been deﬁned by recombination events seen in individuals
expressing the disease phenotype. This region corresponds to4.5 Mb on chromosome 34q16.2–q17.1 (CFA34) extending from
34.9 Mb to 39.4 Mb on the CanFam 2.0 genome assembly.
4. Discussion
Here we have mapped the major locus for osteosarcoma in this
pedigree (i.e. OSA1) to a 10-cM region of chromosome 34. The
pedigree used for this linkage study consisted of a large four
generation pedigree. DNA samples were available for genotyping
from 60 of the 135 individuals in this pedigree. Forty-one of these
DNA samples were collected from a highly informative portion of the
pedigree which allowed for haplotype estimation (Fig. 4A). The
remaining 19 DNA samples were collected from more distantly
related, smaller sibships and contained relatively little information
content for linkage studies (data not shown). The overall pedigree
compares favorably with a larger population of Scottish Deerhounds
previously described [16]; although the following key differences
should be noted: (1) this pedigree was relatively enriched with
affected individuals; and, (2) individuals in this pedigree were on
average older than dogs in our previous report. The ascertainment
process that led to these differences can bias the detection of
covariates that modify disease; in this case age and perhaps other
factors. Furthermore, this age difference can impact the perceived
penetrance of diseases which exhibit a delayed (i.e. age-related) onset
such as osteosarcoma. While no methodology exists for correcting
these sources of bias in canine linkage studies, association studies on
distantly related and outbred populations can be used to identify
covariates that modify disease.
Results from the whole genome linkage analysis effectively
excluded the majority of genomic regions with the exception of loci
on chromosomes 1, 15, 18, 22, 25, and 34. Each of these loci were
associated with LOD scores of N1.0. While statistically the regions on
chromosomes 1, 15, 22, and 25 could not be excluded; haplotype
analysis proximal to these loci identiﬁed several affected recombinant
individuals (data not shown). Given the low levels of recombination
observed in these centromeric regions, they are unlikely to be linked
to the osteosarcoma phenotype segregating in this pedigree. On
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Table 2
Parametric linkage analysis results (all regions with LODN1 under either a recessive or
dominant model).
Chromosome
location
Genetic location,
cM (θ)
Closest
marker
LOD
dominant (θ)
LOD
recessive (θ)
1q11 1.0 FH3325 1.042 −4.716
15q11 1.0 FH5157 −9.436 1.047
22q11 1.0 REN49F22 1.008 −14.591
25q11 1.0 REN54E19 −9.087 1.020
18q25 48.37 REN266I17 2.246 −27.288
34q16.2–q17.1 46.8 REN234E12 5.766 −56.810
Fig. 3. Signiﬁcant LOD scores. LOD scores (blue) and recombination rates (red) for (A)
chromosome18, and (B) chromosome34. Physical length (Mb) isplottedon the x-axis and
is scaled to accommodate varying chromosomal size. Recombination rates and LOD scores
are plotted on the left and right y-axis, respectively. Recombination rateswere determined
in sliding 5 Mb windows as previously described [21]. Ideograms of each chromosome
(left) showing critical regions indicated with blue arrow.
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(Zmax=2.246) was identiﬁed telomeric to marker REN168H09.
Haplotype analysis identiﬁed 3 affected recombinant individuals at
marker REN47J11 (i.e. proximal to the region) but could not be used to
further exclude the region due to the lack of informative markers.
Additional informative markers would be helpful to evaluate this
region as a covariate affecting osteosarcoma in this pedigree.
Statistical evidence for linkage between markers on chromosome
34q16.2–q17.1 and the osteosarcoma phenotype segregating in this
pedigree (OSA1) was strong. The most consistent model assumed
genetic homogeneity (alpha=1.0) within the population and a fully
penetrant dominant trait. In contrast, results of segregation analysis
[16] suggested a reduced penetrance with minimal heterogeneity
(alpha=0.95) could best explain the osteosarcoma phenotype
segregating within the Deerhound population. These minor differ-
ences are likely attributable to the selection process used for the
pedigree studied here. As mentioned previously, this pedigree is
enriched with closely related affected individuals and thus relatively
homogeneous. Furthermore, for diseases that show an age-related
onset it can be difﬁcult to distinguish between non-carrier and non-
penetrant “unaffected” individuals. In this pedigree, the unaffected
dogs were signiﬁcantly older than the unaffected dogs in our previous
report. This age difference would be expected to lower the likelihood
of misclassiﬁcation of unaffected individuals and thus result in an
apparent increase in disease penetrance as seen herein.
Haplotype analysis identiﬁed a 10-cM critical region on CFA34
betweenmarkers FH3836 and REN44K21. This 4.5 Mb region of canine
chromosome 34q16.2–17.1 is syntenic to human chromosome 3q26
[27]. Interestingly, human chromosome 3q26 is associatedwith a high
incidence of loss of heterozygosity in both primary and metastatic
osteosarcoma tumor samples from humans [28,29]. Loss of heterozy-
gosity (LOH) is a genetic event that is thought to result in tumor-
speciﬁc inactivation of suppressor genes and can be detected by
comparing polymorphic markers between tumor and normal tissues
[30]. Consistent loss of heterozygosity at speciﬁc polymorphic
markers is generally considered a good predictor of the presence of
a tumor suppressor gene located close to these markers. Furthermore,
it is well known that most familial cancer syndromes are related to
defects in tumor suppressor genes [31]. By using loss of heterozygos-
ity analysis, a 1-cM critical sub region of human chromosome 3q26
between markers D3S1212 and D3S1246 has been identiﬁed [28]. This
region is syntenic to CFA34 betweenmarkers FH3836 and REN234E12;
the location of the peak LOD score deﬁned in this pedigree.
In human osteosarcomas, other common sites of LOH include
chromosomal arms 13q, 17p, and 18q [28,29]. Chromosomes 13q and
17p are known to contain RB1 and TP53, respectively; tumor
suppressor genes important for osteosarcoma tumorigenesis [32].
Retinoblastoma and Li-Fraumeni syndrome are familial cancer
syndromes associated with defects in these two genes. To date, noFig. 2.Multipoint LOD score results. Results of parametric whole genome linkage analysis fo
(red) models are shown from centromeric to telomeric end (left to right). Genetic distance (c
LOD scores are plotted on the y-axis. Assumptions include complete penetrance and genetifamilial cancer syndromes have been localized to either chromosome
3q or 18q. Several candidate tumor suppressor genes, however, have
been localized to chromosome 3q26 [33–36]. One such gene is the
recently identiﬁed tumor suppressor gene PPM1L [35]. PPM1L encodes
a novel serine-threonine phosphatase in the TGF-beta and BMP
signaling pathways and is thought to play a role in APC mutation-
negative familial colorectal cancer. The canine homologue for PPM1L
is localized within the larger candidate region identiﬁed on canine
chromosome 34.
Another interesting candidate located within this region of human
chromosome 3q26 is the MECOM gene (EVI1 complex locus). MECOM
encodes a nuclear transcription factor, essential for the proliferation/
maintenance of hematopoietic stem cells. Aberrant expression of the
MECOM gene has been associated with a variety of human
hematopoietic malignancies [36]. Interesting, in the Scottish Deer-
hound population previously described [16], and the pedigree herein,
the probability for the development of a hematopoietic malignancy in
the sibling of a dog affected with osteosarcoma is 9% (data not
shown). Given the relatively low population prevalence, this ﬁnding
suggests an extremely high relative risk for hematopoietic malignan-
cies in siblings of affected dogs. The canine homologue of MECOM is
localized within the critical region of CFA34 deﬁned herein and is
another excellent candidate gene for this heritable cancer syndrome
(OSA1). Further evaluation of the Scottish Deerhound for causative
mutations associated with the osteosarcoma phenotype and as a
model of the orthologous human disease is ongoing. This effort willr the OSA1 phenotype. Dominant transmission (blue) and recessive (red) transmission
M) is plotted on the x-axis and is scaled to accommodate the varying chromosomal size,
c homogeneity.
Fig. 4.Haplotype analysis from CFA34. Results are shown centromeric to telomeric end (top to bottom). Affected individuals are shown as blackened circles. The conserved haplotype
shared by affected individuals is illustrated in red. Haplotypes from the most informative portion of the pedigree are shown in “A.”
226 J.C. Phillips et al. / Genomics 96 (2010) 220–227involve genome-wide and regional association studies in other
outbred canine populations with the goal of identifying additional
covariates affecting penetrance (genome-wide) and further narrow-
ing the critical region of CFA34 (regional SNP evaluation).
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